A clinical evaluation of ritipenem acoxil in otorhinolaryngological infections including tonsillitis, pharyngolaryngitis and suppurative sialoadenitis

Abstract

The clinical effects of ritipenem acoxil (RIPM-AC) were examined in 42 patients with tonsillitis, 8 with pharygolaryngitis and 15 with suppurative sialoadenitis and the following results were obtained:
1) The efficacy rate was 86% (25/29) for tonsillitis, 86% (6/7) for pharygolaryngitis, and 92% (11/12) for suppurative sialoadenitis.
2) The bacteriological response was “eradicated” in 39,“replaced” in 1 and “unchanged” in 1. The bacteriological eradication rate was 98%. Of the 55 causative organisms, all but 1 strain of Klebsiella pneumoniae was eradicated, with an eradication rate of 98%.
3) Side effects were observed in 3 (5%) of 63 patients, and abnormal laboratory findings were noted in 1 (3%) of 37 patients, but none of them were severe.
4) The safety rate was 94% (59/63).
5) The usefulness rate 83% (24/29) for tonsillitis, 86% (6/7) for pharygolaryngitis, and 92% (11/12) for suppurative sialoadenitis.
Based on these findings, RIPM-AC is thus considered to be useful in the treatment of tonsillitis, pharyngitis and suppurative sialoadenitis.